Boston Partners Sells 12,151 Shares of DaVita Inc. $DVA

Boston Partners reduced its position in shares of DaVita Inc. (NYSE:DVA) by 13.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 79,074 shares of the company’s stock after selling 12,151 shares during the period. Boston Partners owned 0.11% of DaVita worth $11,264,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of DaVita during the 1st quarter valued at about $364,000. LPL Financial LLC lifted its stake in DaVita by 36.2% in the first quarter. LPL Financial LLC now owns 18,689 shares of the company’s stock valued at $2,859,000 after buying an additional 4,968 shares during the period. Sovran Advisors LLC bought a new stake in shares of DaVita in the 2nd quarter valued at $472,000. Caxton Associates LLP acquired a new position in shares of DaVita in the first quarter valued at approximately $513,000. Finally, Abacus FCF Advisors LLC acquired a new position in DaVita during the 2nd quarter worth approximately $5,632,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Performance

Shares of DaVita stock opened at $119.68 on Friday. DaVita Inc. has a 52 week low of $113.97 and a 52 week high of $179.60. The stock has a market capitalization of $8.45 billion, a PE ratio of 12.33, a price-to-earnings-growth ratio of 0.91 and a beta of 1.13. The stock has a 50 day moving average price of $125.02 and a two-hundred day moving average price of $133.76.

DaVita (NYSE:DVA) last posted its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.17 by ($0.66). The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a return on equity of 815.62% and a net margin of 5.80%.The business’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on DVA shares. TD Cowen lowered their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research note on Monday, November 3rd. Bank of America cut their target price on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Cowen reissued a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research note on Tuesday. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $148.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.